Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2024 | Acute Coronary Syndrome | Research

Ceramides and pro-inflammatory cytokines for the prediction of acute coronary syndrome: a multi-marker approach

Authors: Huiqing Liang, Fangjiang Li, Liang Zhang, Lin Li, Bingyan Guo

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Abstract

Background

There is a growing body of evidence supporting the significant involvement of both ceramides and pro-inflammatory cytokines in the occurrence and progression of acute coronary syndrome (ACS).

Methods

This study encompassed 216 participants whose laboratory variables were analysed using standardised procedures. Parameters included baseline serum lipid markers, comprising total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglycerides (TGs), lipoprotein(a) (LPa), fasting blood glucose, B-natriuretic peptide and hypersensitive C-reactive protein. Liquid chromatography-tandem mass spectrometry measured the concentrations of plasma ceramides. Enzyme-linked immunosorbent assay quantified tumour necrosis factor-α (TNF-α), interleukin 6 (IL6) and IL8. The correlation between ceramides and inflammatory factors was determined through Pearson’s correlation coefficient. Receiver operating characteristic (ROC) curve analysis and multivariate logistic regression evaluated the diagnostic potential of models incorporating traditional risk factors, ceramides and pro-inflammatory cytokines in ACS detection.

Results

Among the 216 participants, 138 (63.89%) were diagnosed with ACS. Univariate logistic regression analysis identified significant independent predictors of ACS, including age, gender, history of diabetes, smoking history, TGs, TNF-α, IL-6, ceramide (d18:1/16:0), ceramide (d18:1/18:0), ceramide (d18:1/24:0), ceramide (d18:1/20:0) and ceramide (d18:1/22:0). Multivariate logistic regression analysis revealed significant associations between gender, diabetes mellitus history, smoking history, LPa, IL-6, ceramide (d18:1/16:0) and ACS. Receiver operating characteristic analysis indicated that model 4, which integrated traditional risk factors, IL-6 and ceramide (d18:1/16:0), achieved the highest area under the curve (AUC) of 0.827 (95% CI 0.770–0.884), compared with model 3 (traditional risk factors and ceramide [d18:1/16:0]) with an AUC of 0.782 (95% CI 0.720–0.845) and model 2 (traditional risk factors and IL-6), with an AUC of 0.785 (95% CI 0.723–0.846) in ACS detection.

Conclusions

In summary, incorporating the simultaneous measurement of traditional risk factors, pro-inflammatory cytokine IL-6 and ceramide (d18:1/16:0) can improve the diagnostic accuracy of ACS.

Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, KimuraT,Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, RigopouloAG, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826. https://doi.org/10.1093/eurheartj/ehad191.CrossRefPubMed

Flego D, Liuzzo G, Weyand CM, Crea F. Adaptive immunity dysregulation in Acute Coronary syndromes: from Cellular and molecular basis to clinical implications. J Am Coll Cardiol. 2016;68(19):2107–17. https://doi.org/10.1016/j.jacc.2016.08.036.CrossRefPubMedPubMedCentral

Liu Y, Huang D, Li B, Liu W, Sooranna SR, Pan X, Huang Z, Guo J. Association between α1-antitrypsin and acute coronary syndrome. Exp Ther Med. 2020;20(5):119. https://doi.org/10.3892/etm.2020.9247.CrossRefPubMedPubMedCentral

Basiak M, Kosowski M, Hachula M, Okopien B. Plasma concentrations of cytokines in patients with combined hyperlipidemia and atherosclerotic plaque before treatment Initiation-A pilot study. Med (Kaunas). 2022;58(5):624. https://doi.org/10.3390/medicina58050624.CrossRef

Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, Sysi-Aho M, Ekroos K, Garcia-Garcia HM, Oemrawsingh RM, Regar E, Koenig W, Serruys PW, van Geuns RJ, Boersma E, Laaksonen R. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015;243(2):560–6. https://doi.org/10.1016/j.atherosclerosis.2015.10.022.CrossRefPubMed

Stith JL, Velazquez FN, Obeid LM. Advances in determining signaling mechanisms of ceramide and role in Disease. J Lipid Res. 2019;60(5):913–8. https://doi.org/10.1194/jlr.S092874.CrossRefPubMedPubMedCentral

Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 Diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58(2):337–43. https://doi.org/10.2337/db08-1228.CrossRefPubMedPubMedCentral

Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Williams KJ, Tabas I. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem. 1998;273(7):4081–8. https://doi.org/10.1074/jbc.273.7.4081.CrossRefPubMed

Weil BR, Canty JM Jr. Ceramide signaling in the coronary microcirculation: a double-edged sword? Circ Res. 2014;115(5):475–7. https://doi.org/10.1161/CIRCRESAHA.114.304589.CrossRefPubMedPubMedCentral

10.

Hla T, Dannenberg AJ. Sphingolipid signaling in metabolic disorders. Cell Metab. 2012;16(4):420–34. https://doi.org/10.1016/j.cmet.2012.06.017.CrossRefPubMedPubMedCentral

11.

Pan W, Dong H, Sun R, Zhao L, Sun M, Li L, Yu X, Liu J, Wu J, Yang F, Yu B. Plasma ceramides in relation to coronary plaque characterization determined by Optical Coherence Tomography. J Cardiovasc Transl Res. 2021;14(1):140–9. https://doi.org/10.1007/s12265-020-09978-3.CrossRefPubMed

12.

Uchida Y, Uchida Y, Kobayashi T, Shirai S, Hiruta N, Shimoyama E, Tabata T. Detection of Ceramide, a risk factor for coronary artery Disease, in human coronary plaques by Fluorescent Angioscopy. Circ J. 2017;81(12):1886–93. https://doi.org/10.1253/circj.CJ-17-0363.CrossRefPubMed

13.

Pan W, Sun M, Wu J, Dong H, Liu J, Gao R, Fang S, Xing L, Hu S, Yu B. Relationship between elevated plasma ceramides and plaque rupture in patients with ST-segment elevation Myocardial Infarction. Atherosclerosis. 2020;302:8–14. https://doi.org/10.1016/j.atherosclerosis.2020.04.008.CrossRefPubMed

14.

Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, Salomaa V, Laaksonen R. Circulating Ceramides Predict Cardiovascular outcomes in the Population-based FINRISK 2002 Cohort. Arterioscler Thromb Vasc Biol. 2016;36(12):2424–30. https://doi.org/10.1161/ATVBAHA.116.307497.CrossRefPubMed

15.

Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113–31. https://doi.org/10.1093/eurheartj/ehaa099.CrossRefPubMed

16.

Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary Heart Disease in men and women. N Engl J Med. 2004;351(25):2599–610. https://doi.org/10.1056/NEJMoa040967.CrossRefPubMed

17.

Bambrough P, Peverelli M, Brown AJ, Giblett JP, Bennett MR, West NEJ, Hoole SP. Trans-myocardial blood Interleukin-6 levels relate to Intracoronary Imaging-defined features of Plaque Vulnerability and Predict Procedure-Induced Myocardial Infarction. Cardiovasc Revasc Med. 2022;39:6–11. https://doi.org/10.1016/j.carrev.2021.10.006.CrossRefPubMed

18.

Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011;121(5):1858–70. https://doi.org/10.1172/JCI43378.CrossRefPubMedPubMedCentral

19.

Pfeilschifter J, Huwiler A. Identification of ceramide targets in interleukin-1 and Tumor necrosis factor-alpha signaling in mesangial cells. Kidney Int Suppl. 1998;67:34–9. https://doi.org/10.1046/j.1523-1755.1998.06707.x.CrossRef

20.

Edsfeldt A, Dunér P, Ståhlman M, Mollet IG, Asciutto G, Grufman H, Nitulescu M, Persson AF, Fisher RM, Melander O, Orho-Melander M, Borén J, Nilsson J, Gonçalves I. Sphingolipids contribute to human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2016;36(6):1132–40. https://doi.org/10.1161/ATVBAHA.116.305675.CrossRefPubMed

21.

Håversen L, Danielsson KN, Fogelstrand L, Wiklund O. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis. 2009;202(2):382–93. https://doi.org/10.1016/j.atherosclerosis.2008.05.033.CrossRefPubMed

22.

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. ESC Scientific Document Group. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of Acute Coronary syndromes in patients presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. https://doi.org/10.1093/eurheartj/ehv320.CrossRefPubMed

23.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P. ESC Scientific Document Group. 2017 ESC guidelines for the management of acute Myocardial Infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute Myocardial Infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77. https://doi.org/10.1093/eurheartj/ehx393.CrossRefPubMed

24.

Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem. 1994;269(5):3125–8.CrossRefPubMed

25.

Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol. 2000;10(2):73–80. https://doi.org/10.1016/s0962-8924(99)01694-3.CrossRefPubMed

26.

Kolesnick R, Golde DW. The sphingomyelin pathway in Tumor necrosis factor and interleukin-1 signaling. Cell. 1994;77(3):325–8. https://doi.org/10.1016/0092-8674(94)90147-3.CrossRefPubMed

27.

Luberto C, Hannun YA. Sphingolipid metabolism in the regulation of bioactive molecules. Lipids. 1999;34 Suppl:S5-11. https://doi.org/10.1007/BF02562221.

28.

Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89(9):763–71. https://doi.org/10.1161/hh2101.099270.CrossRefPubMed

29.

Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, Hochman JS, Goodrich EL, Braunwald E, O’Donoghue ML. Interleukin-6 and the risk of adverse outcomes in patients after an Acute Coronary Syndrome: observations from the SOLID-TIMI 52 (stabilization of Plaque using darapladib-thrombolysis in Myocardial Infarction 52) trial. J Am Heart Assoc. 2017;6(10):e005637. https://doi.org/10.1161/JAHA.117.005637.CrossRefPubMedPubMedCentral

30.

Maloberti A, Intravaia RCM, Mancusi C, Cesaro A, Golia E, Ilaria F, Coletta S, Merlini P, De Chiara B, Bernasconi D, Algeri M, Ossola P, Ciampi C, Riccio A, Tognola C, Ardissino M, Inglese E, Scaglione F, Calabrò P, De Luca N, Giannattasio C. Secondary Prevention and Extreme Cardiovascular Risk evaluation (SEVERE-1), Focus on Prevalence and Associated Risk factors: the Study Protocol. High Blood Press Cardiovasc Prev. 2023. https://doi.org/10.1007/s40292-023-00607-z.CrossRefPubMedPubMedCentral

31.

Bacchiega BC, Bacchiega AB, Usnayo MJ, Bedirian R, Singh G, Pinheiro GD. Interleukin 6 inhibition and coronary artery Disease in a High-Risk Population: a prospective community-based clinical study. J Am Heart Assoc. 2017;6(3):e005038. https://doi.org/10.1161/JAHA.116.005038.CrossRefPubMedPubMedCentral

32.

Qu D, Liu J, Lau CW, Huang Y. IL-6 in Diabetes and cardiovascular Complications. Br J Pharmacol. 2014;171(15):3595–603. https://doi.org/10.1111/bph.12713.CrossRefPubMedPubMedCentral

33.

Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, Lucking AJ, Flather MD, Lees B, Foley CE. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (the MRC-ILA-HEART Study). Trials. 2008;9:8. https://doi.org/10.1186/1745-6215-9-8.CrossRefPubMedPubMedCentral

34.

Li H, Cen K, Sun W, Feng B. Predictive value of blood Interleukin-6 level in patients with Acute Coronary Syndrome: a Meta-analysis. Immunol Invest. 2021;50(8):964–76. https://doi.org/10.1080/08820139.2020.1795876.CrossRefPubMed

35.

Hilvo M, Vasile VC, Donato LJ, Hurme R, Laaksonen R. Ceramides and Ceramide scores: clinical applications for cardiometabolic risk stratification. Front Endocrinol (Lausanne). 2020;11:570628. https://doi.org/10.3389/fendo.2020.570628.CrossRefPubMed

36.

Ren L, Li F, Tan X, Fan Y, Ke B, Zhang Y, Jiang H, Jia L, Wang Y, Du J. Abnormal plasma ceramides refine high-risk patients with worsening Heart Failure. Front Cardiovasc Med. 2023;10:1185595. https://doi.org/10.3389/fcvm.2023.1185595.CrossRefPubMedPubMedCentral

37.

Targher G, Lunardi G, Mantovani A, Meessen J, Bonapace S, Temporelli PL, Nicolis E, Novelli D, Conti A, Tavazzi L, Maggioni AP, Latini R. Relation between plasma ceramides and cardiovascular death in chronic Heart Failure: a subset analysis of the GISSI-HF trial. ESC Heart Fail. 2020;7(6):3288–97. https://doi.org/10.1002/ehf2.12885.CrossRefPubMedPubMedCentral

38.

Yao K, Wang Y, Xu D, Liu X, Shen C, Hu W, Wang Z, Wu R, Tang X, Sun A, Zou Y, Qian J, Wu G, Guo X, Cheng X, Ge J. Effect of combined testing of ceramides with high-sensitive troponin T on the detection of acute coronary syndrome in patients with chest pain in China: a prospective observational study. BMJ Open. 2019;9(7):e028211. https://doi.org/10.1136/bmjopen-2018-028211.CrossRefPubMedPubMedCentral

39.

Pan W, Li L, Sun M, Wang C, Fang S, Yu B. Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation Myocardial Infarction. Int J Cardiol. 2020;320:155–60. https://doi.org/10.1016/j.ijcard.2020.08.010.CrossRefPubMed

40.

Cui S, Li K, Ang L, Liu J, Cui L, Song X, Lv S, Mahmud E. Plasma phospholipids and sphingolipids identify Stent Restenosis after Percutaneous Coronary intervention. JACC Cardiovasc Interv. 2017;10(13):1307–16. https://doi.org/10.1016/j.jcin.2017.04.007.CrossRefPubMed

41.

Maloberti A, Biolcati M, Ruzzenenti G, Giani V, Leidi F, Monticelli M, Algeri M, Scarpellini S, Nava S, Soriano F, Oreglia J, Sacco A, Morici N, Oliva F, Piani F, Borghi C, Giannattasio C. The role of Uric Acid in Acute and Chronic Coronary syndromes. J Clin Med. 2021;10(20):4750. https://doi.org/10.3390/jcm10204750.CrossRefPubMedPubMedCentral

Title: Ceramides and pro-inflammatory cytokines for the prediction of acute coronary syndrome: a multi-marker approach
Authors: Huiqing Liang
Fangjiang Li
Liang Zhang
Lin Li
Bingyan Guo
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Acute Coronary Syndrome
Cytokines
Diabetes
Published in: BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-023-03690-1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ceramides and pro-inflammatory cytokines for the prediction of acute coronary syndrome: a multi-marker approach

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Association of uncertain significance genetic variants with myocardial mechanics and morphometrics in patients with nonischemic dilated cardiomyopathy

The investigation of thrombocytopenia after transcatheter occlusion of patent ductus arteriosus

Exploration of neuron heterogeneity in human heart failure with dilated cardiomyopathy through single-cell RNA sequencing analysis

Comparing coronary artery cross-sectional area among asymptomatic South Asian, White, and Black participants: the MASALA and CARDIA studies

Global longitudinal strain and plasma biomarkers for prognosis in heart failure complicated by diabetes: a prospective observational study

The impact of the time factors on the exercise-based cardiac rehabilitation outcomes of the patients with acute myocardial infarction after percutaneous coronary intervention: a systematic review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page